.
Search
Dr. Jim Januzzi and Dr. C. Michael Gibson discuss the findings from the randomized controlled ATTRIBUTE-CM trial examining the relationship between these biomarkers and clinical outcomes in transthyretin amyloid cardiomyopathy.
Sponsored by an independent educational grant from BridgeBio Inc.
Dr. Dan Judge and Dr. C. Michael Gibson discuss new findings from a study evaluating the differential stabilization of transthyretin (TTR) with acoramidis and tafamidis. The study found greater TTR stabilization with acoramidis across multiple analyses, including in vitro testing of 51 patient samples representing 17 unique TTR variants.
Sponsored by an independent educational grant from BridgeBio Inc.
New insights into the heart-kidney connection in ATTR-CM. Dr. Jeffrey Testani and Dr. C. Michael Gibson discuss new analyses showing that acoramidis was associated with early and sustained kidney-protective effects in patients with ATTR-CM—findings that may help explain the therapy’s early cardiovascular benefits and offer new perspectives on cardiorenal health.
Supported by an independent educational grant from BridgeBio Inc.
Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.
The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]
Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
Dr. Nihar Desai and I discuss how practice is moving toward
We talk about the importance of MDs reviewing AI output and the timing of CT reassessment of risk Sponsored by […]
Dr. Brittany Weber and Dr. C. Michael Gibson discuss: Why Atherosclerosis is All That Really Matters: A Summary for Seamless Integration into Daily Clinical Practice
Sponsored by Cleerly, Women as One and International Atherosclerosis Society.